Apelin-13 dosing & administration
A natural heart hormone that helps your cardiovascular system work better and supports healthy blood flow throughout your body.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Intravenous: Delivered straight into a vein through a drip (IV), done by a clinician.
Bioavailability Complete (about 100%) — delivered straight into the bloodstream.
3 documented dose levels — separate regimens, not a titration schedule
30 nmol/min
Frequency
Continuous infusion
Duration
5 minutes per dose step (research setting)
Apelin-13 is a research peptide given as a short drip into a vein in studies, not by self-injection. This low rate was the first step tested in a human heart study. [4]
100 nmol/min
Frequency
Continuous infusion
Duration
5 minutes per dose step (research setting)
Middle infusion rate used in the human heart study. It increased the heart's output and relaxed blood vessels. [4]
300 nmol/min
Frequency
Continuous infusion
Duration
5 minutes per dose step (research setting)
Highest infusion rate tested in the same human study, producing the strongest effect on heart output and blood pressure. [4]
Timing
Best time to take
Apelin-13 is administered intravenously in a clinical setting. [4] Timing is determined by your healthcare provider based on the treatment protocol and your medical needs.
With food?
IV administration of Apelin-13 is not dependent on meal timing. Your healthcare team will provide specific instructions regarding food and fluid intake around treatment sessions.
If stacking
Apelin-13 should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
- You've tolerated the current dose for the recommended period without significant side effects
- Therapeutic goals haven't been met at the current dose level
- Your healthcare provider recommends dose escalation based on your response
- Lab work or clinical assessments support a higher dose
Decrease if
- Side effects are bothersome or impacting daily life despite management strategies
- You experience any signs of an adverse reaction
- Lab results indicate the need for dose reduction
- Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- Therapeutic goals being met with minimal side effects
- Stable and consistent response to treatment
- Lab values or clinical markers trending in the right direction
- Good tolerance with manageable or absent side effects
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Storage
Before reconstitution
Store Apelin-13 in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, Apelin-13 should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: Intravenous (IV)—rotate sites if applicable
Maintain a consistent schedule for optimal results with Apelin-13. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Is it safe?
Side effects
Commonly reported: Mild changes in blood pressure, Minimal systemic effects in animal studies, Headache (theoretical, based on blood pressure effects), Flushing or warmth at injection site, Mild inflammation at injection site, Dizziness if blood pressure drops too quickly, Allergic reactions to the peptide, Heart rhythm changes (requires monitoring), Blood pressure, heart rate, cardiac function
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Apelin-13
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Apelin-13 should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
- Other heart-active peptides without proper spacing and monitoring — Use with caution—discuss with your healthcare provider.
- ACE inhibitors or ARBs (blood pressure medication - requires careful monitoring) — Use with caution—discuss with your healthcare provider.
- Stimulant compounds that raise heart rate significantly — Use with caution—discuss with your healthcare provider.
Published research
What the studies show
Chen C, Zhao S, Chen Z · 2025
Apelin-13 at 22 μmol/L completely reversed bupivacaine cardiotoxicity in both cell and animal models, improving heart cell function and survival rate from 50% to 100%. The peptide protected mitochondrial structure and increased survival through its APJ receptor interaction.
Contreras Vite JA, Tiffinger A, Théroux L · 2025
A C-terminally modified apelin-13 analog selectively blocked ITO potassium current by 47%, prolonging heart cell action potential without affecting sodium currents. This selective blocking restores electrical balance disrupted in Brugada syndrome.
Yeves AM, Godoy Coto J, Pereyra EV · 2024
Apelin-13 signaling protected heart mitochondria from oxidative damage and enhanced antioxidant defenses in hypertensive hearts. The peptide improved cellular energy production and reduced stress markers in heart tissue.
Japp AG, Cruden NL, Barnes G, et al. · 2010
Intravenous [Pyr1]apelin-13 was infused at 30, 100 and 300 nmol/min (each for 5 minutes) in healthy subjects and heart failure patients, increasing cardiac index and lowering mean arterial pressure and peripheral vascular resistance.
Tatemoto K, Hosoya M, Habata Y, et al. · 1998
The 1998 discovery of apelin: the endogenous ligand for the orphan APJ receptor was isolated from bovine stomach extracts and characterized, including the shorter C-terminal fragments such as apelin-13 that retain full receptor activity.
O'Dowd BF, Heiber M, Chan A, et al. · 1993
The 1993 cloning of the APJ receptor gene: identified as an orphan G-protein coupled receptor related to the angiotensin receptor, located on human chromosome 11, five years before its natural ligand apelin was found.
Davenport AP, Williams TL, Nyimanu D, et al. · 2026
The IUPHAR review of apelin receptor pharmacology: [Pyr1]apelin-13 infused into healthy volunteers increased cardiac output and decreased peripheral resistance without side effects, effects retained in heart failure and pulmonary arterial hypertension patients; covers receptor structure, the apelin peptide family, and agonists in development — no approved apelin medicine exists yet.
Head to head
Apelin-13 compared
Want the full picture?
The complete Apelin-13 research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.